We are live on ! Find out more

SIGA Technologies

SIGA

Market cap $218M

3.04 USD

-0.14

4.4%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

2.99

-0.05

1.64%

1 day

-4.4%

5 days

-2.25%

1 month

-10.59%

3 months

-6.46%

6 months

-33.91%

Year to date

-51.52%

1 year

-63.42%

5 years

-58.07%

10 years

-50%

About: SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.

Employees: 49

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Monday, November 9, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

Continues Canada's commitment to smallpox preparedness for the Canadian Armed Forces Continues Canada's commitment to smallpox preparedness for the Canadian Armed Forces

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

Siga Technologies Q2 Earnings Call Highlights

Siga Technologies NASDAQ: SIGA reported second-quarter product-related revenue of $38 million, driven primarily by deliveries of intravenous TPOXX to the U.S. Strategic National Stockpile and oral TPOXX sales to international customers. The company said the quarter reflected the variable timing of its government-focused procurement business after minimal product revenue in the first quarter.

Siga Technologies Q2 Earnings Call Highlights

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

Siga Technologies, Inc. remains a Hold, as revenue visibility hinges on BARDA contract renewal, with shares down ~40% since April. SIGA's sole commercial product, TPOXX, faces shrinking opportunities after losing EU approval for MPOX although mgmt is developing pediatric and PEP versions. Q1 2026 results showed stagnant revenues, widening losses, and reliance on a $26m BARDA delivery and $13m Asia Pacific contract.

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

Siga Technologies Q1 Earnings Call Highlights

Siga Technologies NASDAQ: SIGA reported a first-quarter loss as product deliveries remained minimal, but management said it expects a pickup in the second quarter tied to an international order and additional deliveries to the U.S. Strategic National Stockpile.

Siga Technologies Q1 Earnings Call Highlights

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2026.

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™